title: Portal but not peripheral serum levels of interleukin 6 could interfere with glucose metabolism in patients with pancreatic cancer.
abstract: Interleukin 6 (IL-6), an autocrine growth factor for many tumors, seems to favour tumor spread to the liver. Our aims were first to evaluate the pattern of portal and systemic IL-6 levels in patients with pancreatic cancer (PC, n = 18) and chronic pancreatitis (CP, n = 22) compared with controls (CS, n = 20); and second, to ascertain whether there was any relation between IL-6 levels and tumor spread or PC-associated Diabetes mellitus. For all subjects, a fasting serum sample was obtained from a cubital vein; a portal serum sample was obtained from nine PC and three CP patients. In cubital and portal sera we measured IL-6, interleukin 1 beta (IL-1b), CA 19-9, c-reactive protein (CRP) and amylase. Systemic IL-6 levels were significantly higher in PC patients than in CS. In PC, portal IL-6 levels were significantly higher than the corresponding systemic values. The same pattern was found in the three CP patients, whereas IL-1b, CA 19-9, CRP and amylase portal levels were the same as systemic values. No correlation was found between PC stage and systemic or portal IL-6 levels. Portal IL-6 levels were correlated with the corresponding fasting serum glucose values. A significant correlation was found between IL-6 values and CRP, ALT, total bilirubin, GGT and creatinine, but not amylase.
  
  
  CONCLUSIONS
  (1) Portal IL-6, which is partly of pancreatic origin, is first metabolised in the liver; (2) Systemic IL-6 reflects hepatic and renal functions rather than local conditions in the pancreas; (3) IL-6 does not appear to influence PC spread; (4) IL-6, which is released in large amounts by the inflamed pancreas, may contribute to determining diabetes, thus interfering with the signal transducing pathways involved in glucose metabolism in liver cells.
authors.affiliation: Dipartimento di Medicina di Laboratorio, Padova, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Fogar
authors.forename: D
authors.initials: D
authors.lastname: Basso
authors.forename: C
authors.initials: C
authors.lastname: Pasquali
authors.forename: M G
authors.initials: MG
authors.lastname: Piva
authors.forename: L
authors.initials: L
authors.lastname: Brigato
authors.forename: M
authors.initials: M
authors.lastname: De Paoli
authors.forename: F
authors.initials: F
authors.lastname: Galeotti
authors.forename: A
authors.initials: A
authors.lastname: Corsini
authors.forename: M
authors.initials: M
authors.lastname: Plebani
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001775:Blood Circulation; D002908:Chronic Disease; D003920:Diabetes Mellitus / Q000097:blood; D005260:Female; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D015850:Interleukin-6 / Q000097:blood*; D008099:Liver / Q000098:blood supply; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000473:pathology; D010195:Pancreatitis / Q000097:blood; D011168:Portal System
chemical_list: D015850:Interleukin-6; D005947:Glucose